Wizmed Logo
One Search
Connect with us
Request a demo

FDA Drug NDCs / Labels

2

Labels
NDA Filings Medical P , Merck Sha

private labels NovaPlus Premier Intalere Northstar Civica BluePoint Schien (HF or GI)
Vertically Integrated (estimated)

FDA Approved Drug Filings

1

Active approvals
Active Approvals / Active Suppliers: ORGANON SU

FDA Drugs Approvals Returned: SUGAMMADEX SODIUM

Active Pharmaceutical Ingredients

20

Active API Holders
Companies with Active APIs AUROBINDO PH , BIOPHORE IND , BRIGHTGENE B , DR REDDYS LA , FRESENIUS KA , GLAND PHARMA , HONOUR LAB L , LEK PHARMACE , MANKIND PHAR , MEDICHEM MAN , MSN LIFE SCI , MYLAN API US , NATCO PHARMA , NEULAND LABO , RUYUAN HEC P , SCINOPHARM T , SOLARA A PHA , SYNTHON BV , TEVA PHARMAC , USV PRIVATE

APIs Returned SUGAMMADEX SODIUM , SUGAMMADEX SODIUM NON STERILE , SUGAMMADEX SODIUM (NON-STERILE , SUGAMMADEX OCTASODIUM

Tentative FDA Drug Approvals

0

Tentative Approvals

Pharma Drug Patents

3

Patents
ORGANON SUB MERCK patent for BRIDION ( SUGAMMADEX SODIUM) for U-1795: REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE with EXPIRY of 2020-08-07

ORGANON SUB MERCK patent for BRIDION ( SUGAMMADEX SODIUM) for U-1795: REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE with EXPIRY of 2021-01-27

ORGANON SUB MERCK patent for BRIDION ( SUGAMMADEX SODIUM) for U-1794: REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK with EXPIRY of 2026-01-27


FDA Drug Exclusivity

4

Exclusivities
ORGANON SUB MERCK SUGAMMADEX SODIUM - BRIDION - EQ 500MG BASE/5ML (EQ 100MG BASE/ML) - NCE:NEW CHEMICAL ENTITY -2020-12-15
ORGANON SUB MERCK SUGAMMADEX SODIUM - BRIDION - EQ 200MG BASE/2ML (EQ 100MG BASE/ML) - NCE:NEW CHEMICAL ENTITY -2020-12-15
ORGANON SUB MERCK SUGAMMADEX SODIUM - BRIDION - EQ 500MG BASE/5ML (EQ 100MG BASE/ML) - M-262:MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES) -2023-06-09
ORGANON SUB MERCK SUGAMMADEX SODIUM - BRIDION - EQ 200MG BASE/2ML (EQ 100MG BASE/ML) - M-262:MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES) -2023-06-09

Federal Supply Schedule Pricing

1

Vendors on FSS
Companies on Federal Supply Schedule Merck Sharp & Dohme Corporation

Pharmaceutical Drugs on Federal Supply Schedule SUGAMMADEX 100MG/ML INJ,2ML , SUGAMMADEX 100MG/ML INJ,5ML

Shared Drug Filings

1

Filings
See more under details

FDA Drug Shortage

0

Listed
Currently in Shortage 0
Drug Shortage Resolved 0
Drug to be Discontinued 0

Paragraph IV Drug Files

1

Listings
Bridion 22225 ( Sugammadex Sodium Injection 200 mg/2 mL and 500 mg/5 mL ) had a patent submission date of 2019-12-16 and has a current 180 day status of _ . There are _ 14 ANDAs submitted. The date of the last PIV qualifying patent is _ 2021-01-27. The date of the first applicant approval is _

Compounded Presentations

0

Total Returned
Compounders Returned

National Average Drug Acquisition Cost

0

FDA Drugs
List of approved drugs with a NADAC

Search SUGAMMADEX FDA drug labels to production site status and API suppliers

Better than the FDA Orange Book Search

Enter a drug and/or company below

See some of the popular searches here. Some are large and may take a while to load. These popular searches include Company Search Pfizer, Company Search Fresenius and Drug Search Sugammadex

It is time to stop searching drugs FDA labels for SUGAMMADEX

Use Wizmed's ONE SEARCH to consolidate over a dozen pharma databases


Let's be honest, information on FDA approved drugs is extremely disparate. Upon FDA drug approval, details on FDA labels are sent to multiple agencies who publish different information. Not to mention, all the competitive intelligence drug information you are seeking is redacted and located in different databases.

Wizmed has taken pharmaceutical research to the next level.


Wizmed is able to read FDA drug labels from sources like the FDA orange book and openFDA and extract key information not in databased such as private labels and FDA drug shortages. At the same time, the team has developed golden keys to match up pharma NDCs with FDA communication letters regarding that drug.

Did you know that sometimes those letters even include secrets like drug expiry shelf life and the API suppliers?


Wizmed does and links up the FDA letters by drug NDC and you can access it in the details of a drug page, See Example . If that was not enough for your to use Wizmed. We even use fuzzy lookups to make estimations on which FDA registered locations are making active pharmaceutical ingredients to drive some insight into where your pharmaceuticals are made.

Did you know that sometimes those letters even include secrets like drug expiry shelf life and the API suppliers?


Wizmed does and links up the FDA letters by drug NDC and you can access it in the details of a drug page, See Example . If that was not enough for your to use Wizmed. We even use fuzzy lookups to make estimations on which FDA registered locations are making active pharmaceutical ingredients to drive some insight into where your pharmaceuticals are made.

Data Sources 200,000 records

Dailymed - Continuously Updates
OpenFDA - Continuous Updates
Federal Supply Schedule Pricing - Daily
Drugs@FDA - Weekly
Orange Book - Weekly
483s - Weekly
Warning Letters - Weekly
Drug Patents - Weekly
FDA Inspections - Weekly
DMF files - Quarterly
Data dependant on timing of updates to source data. WIZMED nor any of its agencies, contractors, subcontractors or employees does not make any warranties, expressed or implied, with respect to data contained in these databases or files, and, furthermore, assume no liability for any party's use, or the results of such use, of any part of the database or files.

Need help understanding all the information? Feel free to contact us or view our video tutorials. WIZMED sources is data from the FDA, Dailymed, Medicaid data and other data sources and uses calculations to attempt to align datasets. The data feeds may run night, weekly and/or quarterly depending on data source. WIZMED nor any of its agencies, contractors, subcontractors or employees does not make any warranties, expressed or implied, with respect to data contained in these databases or files, and, furthermore, assume no liability for any party's use, or the results of such use, of any part of the database or files.